| Literature DB >> 25591816 |
Huiqing Shi1,2, Fengjun Sun3, Jianhong Chen4, Qianyi Ou5, Wei Feng6, Xiaolan Yong7, Peiyuan Xia8.
Abstract
BACKGROUND: Escherichia coli is one of the most common clinical pathogens causing nosocomial infection. The widespread cefotaxime-beta lactamases (CTX) has increased the multidrug resistance (MDR) of E. coli and has brought great trouble to the doctor treating the infection.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25591816 PMCID: PMC4299296 DOI: 10.1186/s12941-015-0063-7
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Primers used to amplify ESBL resistance genes
|
|
|
|---|---|
| CTX-M group Ia | GACGATGTCACTGGCTGAGC |
| AGCCGCCGACGCTAATACA | |
| CTX-M group IIb | GCGACCTGGTTAACTACAATCC |
| CGGTAGTATTGCCCTTAAGCC | |
| CTX-M group IIIc | CGCTTTGCCATGTGCAGCACC |
| GCTCAGTACGATCGAGCC | |
| CTX-M group IVd | GCTGGAGAAAAGCAGCGGAG |
| GTAAGCTGACGCAACGTCTG | |
| CTX-M group Ve | GCACGATGACATTCGGG |
| AACCCACGATGTGGGTAGC | |
| TEM | CATTTCCGTGTCGCCCTTATTC |
| CGTTCATCCATAGTTGCCTGAC | |
| SHV | AGCCGCTTGAGCAAATTAAAC |
| ATCCCGCAGATAAATCACCAC | |
| OXAf | GGCACCAGATTCAACTTTCAAG |
| GACCCCAAGTTTCCTGTAAGTG | |
| VEB | CATTTCCCGATGCAAAGCGT |
| CGAAGTTTCTTTGGACTCTG | |
| PER | GCTCCGATAATGAAAGCGT |
| TTCGGCTTGACTCGGCTGA | |
| GES | AGTCGGCTAGACCGGAAAG |
| TTTGTCCGTGCTCAGGAT |
aCTX-M-1, −3, −10 to −12, −15 (UOE-1), −22, −23, −28, −29, and −30.
bCTX-M-2, −4 to −7, and −20 and Toho-1.
cCTX-M-8.
dCTX-M-9, −13, −14, −16 to −19 and −21, and −27 and Toho-2.
eCTX-M-25 and −26.
fOXA-1.
Antimicrobial susceptibility of ESBL-producing isolates from different areas
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Ampicillin | 100 | 100 | 100 | 100 | 100 |
| Piperacillin | 100 | 100 | 100 | 100 | 93.3 |
| Cefotaxime | 94.7 | 100 | 100 | 100 | 90 |
| Cefepime | 68.4 | 95.2* | 93.3 | 90 | 83.3 |
| Cefuroxime | 100 | 100 | 100 | 100 | 96.7 |
| Cefoxitin | 15.8 | 23.8 | 36.7 | 16.7 | 20 |
| Ceftazidime | 26.3 | 61.9* | 56.7* | 63.3* | 53.3 |
| Aztreonam | 5.3 | 61.9** | 73.3** | 76.7** | 60** |
| Imipenem | 0 | 0 | 3.3 | 6.7 | 0 |
| Meropenem | 0 | 0 | 6.7 | 0 | 0 |
| Amoxicillin/Clavulanic acid | 84.2 | 9.5** | 43.3** | 50* | 20** |
| Ampicillin/Sulbactam | 73.7 | 71.4 | 80 | 83.3 | 76.7 |
| Piperacillin/Tazobactam | 5.3 | 0 | 23.3 | 3.3 | 6.7 |
| Trimethoprim-sulfamethoxazole | 78.9 | 85.7 | 83.3 | 83.3 | 73.3 |
| Ciprofloxacin | 68.4 | 90.5 | 70 | 76.7 | 60 |
| Levofloxacin | 47.4 | 90.5** | 70 | 76.7* | 60 |
| Amikacin | 5.3 | 0 | 16.7 | 6.7 | 6.7 |
| Gentamycin | 52.6 | 85.7* | 63.3 | 66.7 | 76.7 |
**P < 0.01 and *P < 0.05.
Distribution of ESBL resistance genes in different areas
|
|
|
|
|
| |
|---|---|---|---|---|---|
| blaCTX-M-1 group | 57.9(11) | 42.9(9) | 83.3(25) | 83.3(25) | 56.7(17) |
| blaCTX-M-9 group | 68.4(13) | 71.4(15) | 53.3(16) | 26.7(8) | 63.3(19) |
| TEM | 63.2(12) | 85.7(18) | 96.7(29) | 83.3(25) | 86.7(26) |
| SHV | 0(0) | 14.3(3) | 30.0(9) | 13.3(4) | 23.3(7) |
| OXA | 10.5(2) | 33.3(7) | 26.7(8) | 16.7(5) | 20.0(6) |
| VEB | 0(0) | 0(0) | 16.7(5) | 0(0) | 6.7(2) |